Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2023
Reporting Period: Event date October 24, 2023; Press release issued October 30, 2023.
Context: The Company, an emerging growth company, entered into an exclusive licensing agreement with Georgetown University regarding intellectual property for predictive biomarkers in radiation therapy.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for a specific reporting period.
- Upfront Payment: The filing states the Company will make an upfront payment but does not disclose the specific amount.
- Recurring Fees: Yearly maintenance fees are required under the agreement.
- Royalties: Upon FDA approval and commercial sale, the Company owes a guaranteed minimum royalty annually plus 5% of Net Sales.
- Termination Fee: The Company may terminate the agreement by paying a $15,000 fee after 90 days' notice if development/sales cease.
Material Changes
The primary material change is the execution of the exclusive License Agreement with Georgetown University on October 24, 2023.
- Intellectual Property: Acquisition of worldwide rights to "Predictive Biomarkers for Adverse Effects of Radiation Therapy" (U.S. Patent Application No. 17/476,184).
- Development Scope: Rights granted for developing processes or methods in the field of oncology.
- Ownership: The IP was developed by the Company's CEO and Principal Scientist alongside Georgetown employees.
Guidance, Outlook, and Risks
Outlook and Milestones: Future payments are contingent on achieving specific development goals, including initiating a validation clinical trial, obtaining regulatory approval, and reaching fundraising and sales milestones.
Risks and Contingencies:
- Termination by Licensor: Georgetown may terminate the agreement if the Company fails to make milestone payments (uncured within 60 days), fails to perform material provisions (uncured within 30 days), assigns IP to creditors, is adjudicated bankrupt, intentionally underreports payments, or fails to maintain adequate insurance.
- Termination by Company: The Company may terminate with 90 days' notice and a $15,000 fee if it ceases development or sales.
- Audit Rights: Georgetown retains the right to inspect books and records with 15 business days' notice.
Investor Verification Checklist
- Verify the specific dollar amount of the upfront payment and yearly maintenance fees, as these are not disclosed in the summary text.
- Review the full text of the License Agreement (Exhibit 10.1) for redacted details regarding milestone payment thresholds.
- Confirm the Company's current cash position to assess its ability to fund the upfront payment and future milestone obligations.
- Monitor the status of the validation clinical trial required to trigger subsequent milestone payments.